BOCA RATON, Fla.--(BUSINESS WIRE)--Jan. 7, 2016-- TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the pricing of an underwritten public offering of $125 million of shares of its common stock, offered at a price of $8.25 per share. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $125 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional 15% of the shares of common stock. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about January 12, 2016, subject to the satisfaction of customary closing conditions.

Goldman, Sachs & Co. and Cowen and Company are acting as joint bookrunning managers for the offering. Stifel and Guggenheim Securities are acting as joint lead managers for the offering.

TherapeuticsMD intends to use a majority of the proceeds of the offering to fund commercialization activities for TX-004HR, its applicator-free vaginal estradiol softgel drug candidate, for other research, clinical trials, clinical formulation and development and for working capital and general corporate purposes.

TherapeuticsMD has filed a shelf registration statement on Form S-3, including a prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission (the “SEC”), relating to the public offering of the shares of common stock described above. Before buying any shares of TherapeuticsMD’s common stock in the offering, you should carefully read the prospectus supplement and the accompanying prospectus, together with the information incorporated therein. These documents contain important information that you should consider when making your investment decision. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282-2198, by calling (866) 471-2526 or by emailing prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC at c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by phone (631) 274-2806 / Fax (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD® and BocaGreenMD® brands.

Forward Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that TherapeuticsMD intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and TherapeuticsMD undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of TherapeuticsMD’s control. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, risks and uncertainties associated with TherapeuticsMD’s business and finances in general and other risks described in the sections titled “Risk Factors” in TherapeuticsMD’s filings with the SEC, including its most recent Annual Report on Form 10-K and other filings with the SEC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005313/en/

Source: TherapeuticsMD, Inc.

TherapeuticsMD, Inc.
Daniel A. Cartwright, 561-961-1900
Chief Financial Officer
Dan.Cartwright@TherapeuticsMD.com